Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesnatilimab as Add-on to SOC in Active Crohn's Disease
NCT04655807Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NNC0142-0002 in Crohn's disease (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Planned start Mar 2021; status: withdrawn.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04655807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655807.